Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
Akinori Sasaki, Yoshiaki Nakamura, Saori Mishima et al. · Gastric Cancer · 2019
Cited by 161 works. doi:10.1007/s10120-018-00922-8 Open-access PDF
Authors
- Akinori Sasaki
- Yoshiaki Nakamura
- Saori Mishima
- Akihito Kawazoe
- Yasutoshi Kuboki
- Hideaki Bando
- Takashi Kojima
- Toshihiko Doi
- Atsushi Ohtsu
- Takayuki Yoshino
- Takeshi Kuwata
- Tetsuo Akimoto
- Kohei Shitara
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer